Literature DB >> 32061158

Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a problematic entity.

Klaudia Zajkowska1, Janusz Kopczyński2, Stanisław Góźdź3, Aldona Kowalska4.   

Abstract

Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) is a borderline thyroid tumour formerly known as noninvasive encapsulated follicular variant of papillary thyroid carcinoma. The prevalence of NIFTP is estimated at 4.4-9.1% of all papillary thyroid carcinomas worldwide; however, the rate of occurrence of NIFTP is eight times lower in Asian countries than in Western Europe and America. At the molecular level, NIFTP is characterised by the lack of BRAF V600E and BRAF V600E-like mutations or other high-risk mutations (TERT, TP53), and a high rate of RAS mutations, which is similar to other follicular-pattern thyroid tumours. The diagnosis of NIFTP can only be made after histological examination of the entire tumour removed during surgery, and is based on strictly defined inclusion and exclusion criteria. Although the diagnosis is postoperative, the combination of certain findings of preoperative tests including ultrasonography, cytology, and molecular testing may raise suspicion of NIFTP. These tumours can be effectively treated by lobectomy, although total thyroidectomy remains an option for some patients. Radioactive iodine and thyroid stimulating hormone suppression therapy are not required. NIFTP has an extremely good prognosis, even when treated conservatively with lobectomy alone. Nevertheless, it cannot be considered as a benign lesion. The risk of adverse outcomes, including lymph node and distant metastases, is low but not negligible.

Entities:  

Year:  2020        PMID: 32061158     DOI: 10.1530/EC-19-0566

Source DB:  PubMed          Journal:  Endocr Connect        ISSN: 2049-3614            Impact factor:   3.335


  6 in total

1.  Synchronous Parathyroid Carcinoma and Noninvasive Follicular Thyroid Neoplasm With Papillary-Like Nuclear Features.

Authors:  Ahmed Alajaimi; Noor Altooq; Nisha Chandran; Yaser Alderazi
Journal:  Cureus       Date:  2022-04-10

2.  Three-dimensional telomere profiles in papillary thyroid cancer variants: A pilot study.

Authors:  Aline Rangel-Pozzo; Tinuccia Dettori; Daniela Virginia Frau; Federica Etzi; John Gartner; Garbor Fisher; Roberta Vanni; Sabine Mai; Paola Caria
Journal:  Bosn J Basic Med Sci       Date:  2022-06-01       Impact factor: 3.759

Review 3.  Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP): Tumour Entity with a Short History. A Review on Challenges in Our Microscopes, Molecular and Ultrasonographic Profile.

Authors:  Ivana Kholová; Elina Haaga; Jaroslav Ludvik; David Kalfert; Marie Ludvikova
Journal:  Diagnostics (Basel)       Date:  2022-01-20

Review 4.  Combinatorial Therapies in Thyroid Cancer: An Overview of Preclinical and Clinical Progresses.

Authors:  Gheysen Laetitia; Saussez Sven; Journe Fabrice
Journal:  Cells       Date:  2020-03-30       Impact factor: 6.600

5.  Molecular Correlates and Nuclear Features of Encapsulated Follicular-Patterned Thyroid Neoplasms.

Authors:  Chan Kwon Jung; Andrey Bychkov; Dong Eun Song; Jang-Hee Kim; Yun Zhu; Zhiyan Liu; Somboon Keelawat; Chiung-Ru Lai; Mitsuyoshi Hirokawa; Kaori Kameyama; Kennichi Kakudo
Journal:  Endocrinol Metab (Seoul)       Date:  2021-02-24

6.  ANXA1 (Annexin A1) regulated by MYC (MYC proto-oncogene) promotes the growth of papillary thyroid carcinoma.

Authors:  Xiaomei Ying; Liang Chen; Jiaheng Xie; Yiming Hu; Qingqing Wu; Liyu Cao; Hongzhu Yu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.